GlassScriptPhysician profile
Norina Hall
NPI 1366140535
$6,306.14
in general payments reported to CMS, 2019-2025
46 companies · $1,359 in 2025
The $1,359 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,745 · 2024: $3,202 · 2025: $1,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,098 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,098.15 |
| Education | $207.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $846.45 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $726.12 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $603.36 | 2023-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $502.43 | 2023-2025 | Enhertu, Calquence, Lynparza |
| Janssen Biotech, INC. | $398.18 | 2023-2025 | Rybrevant, Tecvayli, Carvykti |
| Pfizer INC. | $314.33 | 2023-2025 | |
| Daiichi Sankyo INC. | $200.22 | 2023-2025 | Enhertu |
| Agios Pharmaceuticals, INC. | $174.36 | 2023-2025 | Pyrukynd |
| Lilly USA, LLC | $161.99 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Ipsen Biopharmaceuticals, INC | $148.95 | 2023-2025 | Onivyde, Somatuline Depot |
| Astellas Pharma US INC | $135.93 | 2023-2025 | Vyloy, Padcev, Xospata |
| Mirati Therapeutics, INC. | $133.99 | 2023-2024 | Krazati |
| Novartis Pharmaceuticals Corporation | $123.92 | 2024-2025 | |
| Coherus Oncology, INC. | $123.37 | 2023-2024 | |
| Emmaus Medical, INC. | $118.52 | 2023-2024 | Endari |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $108.92 | 2024-2025 | Reblozyl, Opdualag |
| Aveo Pharmaceuticals, INC. | $108.74 | 2023-2025 | Fotivda |
| Progenics Pharmaceuticals, INC. | $100.99 | 2023-2024 | Pylarify |
| Pharmaessentia USA Corporation | $99.66 | 2024-2025 | Besremi |
| Exelixis INC. | $90.47 | 2023-2024 | Cabometyx |
| Jazz Pharmaceuticals INC. | $87.76 | 2024 | |
| Abbvie INC. | $75.12 | 2024-2025 | |
| Genzyme Corporation | $74.00 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.78 | 2024-2025 | Fruzaqla, Alunbrig |
| Glaxosmithkline, LLC. | $73.28 | 2023-2025 | Shingrix, Jemperli, Zejula |
| Gilead Sciences, INC. | $66.22 | 2023-2024 | |
| Emd Serono, INC. | $62.33 | 2023-2025 | Bavencio |
| Eisai INC. | $56.02 | 2024 | |
| Sun Pharmaceutical Industries INC. | $56.02 | 2024 | |
| Puma Biotechnology, INC. | $50.28 | 2024 | |
| Genentech USA, INC. | $49.00 | 2024 | Tecentriq, Perjeta, Phesgo |
| Karyopharm Therapeutics INC. | $34.44 | 2023 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.38 | 2025 | |
| Seagen INC. | $28.93 | 2023 | Padcev |
| Immunogen, INC. | $27.74 | 2023 | Elahere |
| Fresenius Kabi USA, LLC | $26.44 | 2023 | Stimufend |
| Springworks Therapeutics, INC. | $26.31 | 2025 | |
| Adc Therapeutics America, INC. | $26.16 | 2025 | |
| Rigel Pharmaceuticals, INC. | $24.56 | 2023 | Tavalisse, Rezlidhia |
| Azurity Pharmaceuticals, INC. | $22.42 | 2025 | Danziten |
| Sobi, INC | $21.85 | 2024 | |
| Tempus Ai, INC | $21.57 | 2025 | Xt Cdx |
| Stemline Therapeutics INC. | $19.29 | 2024 | Orserdu |
| Cumberland Pharmaceuticals, INC. | $18.52 | 2024 | Sancuso |
| Spectrum Pharmaceuticals INC. | $16.65 | 2024 | Rolvedon |
| Chiesi USA, INC. | $16.17 | 2023 | Ferriprox |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norina Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.